公开(公告)号：WO2005001087A3

公开(公告)日：2005-03-24

申请号：PCT/US2004018964

申请日：2004-06-10

Applicant: REGENERON PHARMA ,  ECONOMIDES ARIS N ,  VALENZUELA DAVID M ,  DAVIS SAMUEL ,  YANCOPOULOS GEORGE

Inventor： ECONOMIDES ARIS N ,  VALENZUELA DAVID M ,  DAVIS SAMUEL ,  YANCOPOULOS GEORGE

IPC: A01K67/027 ,  C12N5/08 ,  C12N15/90

CPC classification number: C12N15/85 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2217/075 ,  A61D19/04 ,  C12N15/907 ,  C12N2800/30 ,  C12N2830/42 ,  C12N2840/44

Abstract: Methods of creating mutations in genomic exons by inserting introns into the genomic exons via homologous recombination. Also, methods are provided for introducing modifications into genomic exons by inserting introns into the genomic exons via homologous recombination such that a mature mRNA transcript produced from a genomic region of the genome comprising the genomic exon does not contain the modification are provided. The methods provide for a rapid method for introducing mutations and/or modifications of any type into a mammalian cell genome.

Abstract translation: 通过同源重组将内含子插入基因组外显子从而在基因组外显子中产生突变的方法。 此外，提供了通过同源重组将插入子插入基因组外显子从而将修饰引入基因组外显子的方法，从而提供了从包含基因组外显子的基因组的基因组区域产生的成熟mRNA转录物不含修饰。 该方法提供了用于将任何类型的突变和/或修饰引入哺乳动物细胞基因组的快速方法。

公开(公告)号：WO0055193A3

公开(公告)日：2001-01-18

申请号：PCT/US0005537

申请日：2000-03-02

Applicant: REGENERON PHARMA ,  ECONOMIDES ARIS N

Inventor： ECONOMIDES ARIS N

IPC: A61K38/00 ,  C07K14/475 ,  C12N5/10 ,  A61K38/18 ,  A61K39/395 ,  C07K16/22 ,  C12N15/62 ,  C12N15/63

CPC classification number: C07K14/475 ,  A61K38/00 ,  A61K2039/505 ,  C07K2319/00

Abstract: D AN/ C erberus Related protein 6 (DCR6) polypeptides and related nucleic acids are provided. Included are natural (DCR6) homologs from several species and polypeptides comprising a (DCR6) domain having specific activity. The polypeptides may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and oligonucleotide primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.

Abstract translation: 提供了相关蛋白质6（DCR6）多肽和相关核酸。 包括来自几种物种的天然（DCR6）同源物和包含具有特定活性的（DCR6）结构域的多肽。 多肽可以用受试核酸从转化的宿主细胞重组产生。 还提供了能够与公开的基因，特异性结合剂和制备和使用本发明组合物的方法特异性杂交的分离的杂交探针和寡核苷酸引物。

公开(公告)号：WO2016039796A3

公开(公告)日：2016-06-16

申请号：PCT/US2015000100

申请日：2015-09-14

Applicant: REGENERON PHARMA

Inventor： HATSELL SARAH J ,  ECONOMIDES ARIS N ,  IDONE VINCENT J

IPC: C07K16/22 ,  A61K31/519 ,  A61K38/17 ,  A61P19/00 ,  C07K16/28

CPC classification number: C07K16/18 ,  A61K38/179 ,  A61K39/39533 ,  A61K2039/505 ,  C07K14/705 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2319/30

Abstract: Methods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided. Such methods involve administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist or an activin receptor type 1 (ACVRl) antagonist. Antagonists include fusion proteins of one or more extracellular domains (ECDs) of ACVR2A, ACVR2B and/or ACVRl and the Fc domain of an immunoglobulin heavy chain, and antibodies against ACVR2A, ACVR2B, ACVRl or Activin A.

Abstract translation: 提供治疗骨纤维增生异常进展（FOP）的方法。 此类方法涉及向具有FOP的受试者施用2A型活化素受体（ACVR2A）和/或2B型活化素受体（ACVR2B）拮抗剂或1型活化素受体（ACVR1）拮抗剂的有效方案。 拮抗剂包括ACVR2A，ACVR2B和/或ACVR1的一个或多个细胞外结构域（ECD）和免疫球蛋白重链的Fc结构域的融合蛋白，以及针对ACVR2A，ACVR2B，ACVR1或激活素A的抗体。

公开(公告)号：WO0236789A2

公开(公告)日：2002-05-10

申请号：PCT/US0145375

申请日：2001-10-31

Applicant: REGENERON PHARMA ,  ECONOMIDES ARIS N ,  MURPHY ANDREW J ,  VALENZUELA DAVID M ,  FRENDEWEY DAVID ,  YANCOPOULOS GEORGE D

Inventor： ECONOMIDES ARIS N ,  MURPHY ANDREW J ,  VALENZUELA DAVID M ,  FRENDEWEY DAVID ,  YANCOPOULOS GEORGE D

IPC: C12N15/00 ,  A01K67/027 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79 ,  C12N15/90 ,  C12Q1/68 ,  C12N15/85

CPC classification number: A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  C12N15/907

Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous genes(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

Abstract translation: 一种用于工程化和利用大型DNA载体通过同源重组靶向并以任何所需方式修饰真核细胞中的内源基因和染色体基因座的方法。 用于真核细胞的这些大的DNA靶向载体，称为LTVEC，衍生自克隆基因组DNA的片段，大于通常用于在真核细胞中进行同源靶向的其它方法通常使用的那些。 还提供了检测真核细胞的快速和方便的方法，其中LTVEC已经正确靶向和修饰所需的内源基因或染色体基因座（基因座）以及这些细胞用于产生具有遗传修饰的生物体。